Immuneering Corporation
IMRX
$1.54
$0.096.21%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 8.44% | -7.97% | |||
| Depreciation & Amortization | 0.00% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -16.56% | 21.50% | |||
| Operating Income | 16.56% | -21.50% | |||
| Income Before Tax | 16.65% | -23.66% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 16.65% | -23.66% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 16.65% | -23.66% | |||
| EBIT | 16.56% | -21.50% | |||
| EBITDA | 16.64% | -21.66% | |||
| EPS Basic | 27.16% | -18.85% | |||
| Normalized Basic EPS | 27.14% | -17.80% | |||
| EPS Diluted | 27.16% | -18.85% | |||
| Normalized Diluted EPS | 27.14% | -17.80% | |||
| Average Basic Shares Outstanding | 14.43% | 4.05% | |||
| Average Diluted Shares Outstanding | 14.43% | 4.05% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||